News
Public · Published
Wells Fargo maintains Ultragenyx Pharmaceutical at Overweight, raises price target to $19 from $18
Wells Fargo kept its Overweight rating on Ultragenyx Pharmaceutical and raised its price target to $19 from $18. The article says the new target is a 5.6% increase and implies 14.3% upside from the November 3 closing price of $16.63.
Published:
Updated:
What happened
Wells Fargo kept its Overweight rating on Ultragenyx Pharmaceutical and raised its price target to $19 from $18. The article says the new target is a 5.6% increase and implies 14.3% upside from the November 3 closing price of $16.63.
Confirmed
Global impact / market context
The higher target signals a more favorable view of the shares from Wells Fargo, but the rating itself does not change the company’s revenue, costs, or cash available. Any investor impact depends on whether others act on the view and whether the company’s results support it.
Analyst inference
The article reports one analyst’s target change, not a company announcement or a change in Ultragenyx’s business outlook. The stated upside is measured against the November 3 close, so it is a comparison to that past price rather than a guaranteed return.
Analyst inference
What to watch
- Check whether Wells Fargo gives additional reasons for the higher target; the supplied article does not explain what changed in its outlook or valuation. Analyst inference
- Watch for any further rating or target changes for Ultragenyx, since the article provides no other analysts’ views or later recommendations. Analyst inference
- Compare future company updates with the assumptions behind the $19 target; the article gives no operating forecasts or evidence that the target will be reached. Analyst inference
Evidence
- Original source link unavailable